Patient-Derived Xenograft Models of Breast Cancer

Breast cancer is the leading type of cancer diagnosed in women worldwide and requires predictive research models for preclinical drug development. Patient-derived xenograft (PDX) models provide a true representation of the human heterogeneity and can be used to test the efficacy of novel agents against drug resistance. The CrownBio PDX models of breast cancer collection consists of a wide range of models, including 17 triple negative breast cancer (TNBC) models as well as ER+, PR+, and HER2+ models. More

Benefits of CrownBio’s Breast Cancer PDX Models

Our breast cancer patient-derived xenograft models offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient-derived xenografts reflect the heterogeneity and diversity of the human patient population. PDX gives you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® Breast cancer PDX model collection is well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER SUBTYPE # per page
BR0438 HER2 (1+ or 2+), ER (-), PR (-)CLICK TO VIEW
BR10014 TNBCCLICK TO VIEW
BR10508 NACLICK TO VIEW
BR10539 TNBCCLICK TO VIEW
BR10562 HER2 (+)CLICK TO VIEW
BR10583 NACLICK TO VIEW
BR10607 NACLICK TO VIEW
BR1115 HER2 (0.5+), ER (+), PR (+)CLICK TO VIEW
BR1282 TNBCCLICK TO VIEW
BR1283 TPBCCLICK TO VIEW
BR1458 TNBCCLICK TO VIEW
BR1467 AdenocarcinomaCLICK TO VIEW
BR1474 TNBCCLICK TO VIEW
BR2014 TNBCCLICK TO VIEW
BR2397 N/ACLICK TO VIEW
BR2401 N/ACLICK TO VIEW
BR2543 NACLICK TO VIEW
BR3058 NACLICK TO VIEW
BR3116 TNBCCLICK TO VIEW
BR3267 ER (+)CLICK TO VIEW